Minco Capital Corp is focused on utilizing its working capital position, industry contacts and internal expertise to identify, evaluate and invest in assets that have the capacity to generate returns and growth. The company invests in publicly traded and privately held corporations as well as taking indirect and direct ownership stakes in resource projects. Its types of investments may include common shares, preferred shares, warrants, royalties, convertible debentures, bridge loans, and other investment vehicles. It has one segment which is the acquisition and sale of investments in other companies.
相关临床试验
29
1 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
1
3.5%
已完成
15
51.7%
终止
6
20.7%
Unknown
1
3.5%
撤回
5
17.2%
Withheld
1
3.5%
- The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration. - Microneedle devices market is expected to reach $2.11 billion in 2024 and grow at a faster CAGR of 6.2%, reflecting technological innovations and applications in personalized medicine. - Key market players include Antares Pharma (acquired by Halozyme), INOVIO Pharmaceuticals, PharmaJet, and 3M, with technological advancements focusing on improved safety, accuracy, and patient compliance.
- A comprehensive new industry report analyzes over 1,670 clinical-stage partnering agreements in pharma and biotech from 2020-2025, providing unprecedented access to deal structures and financial terms. - The report reveals detailed intelligence on how licensing agreements typically grant exclusive rights across Phase I-III trials, with multi-component structures involving collaborative R&D and commercialization strategies. - Business development professionals can now access actual contract documents and payment triggers often missing from press releases, enabling more effective negotiation strategies and competitive deal structuring.
